Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.39 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015385 | 0.91 | PPARG (0.33) | PTGESCYP3A4CYP3A5PPARG | |
| SCHEMBL3009742 | 0.91 | MAP4K1 (0.37) | PTGESMAP4K1MCHR1PPARG | |
| SCHEMBL3001788 | 0.82 | POLB (0.34) | MAP4K1MCHR1PPARG | |
| SCHEMBL3000796 | 0.75 | MAP4K1 (0.35) | MAP4K1MCHR1 | |
| SCHEMBL3000984 | 0.75 | MCHR1 (0.36) | MAP4K1MCHR1 | |
| SCHEMBL3006485 | 0.74 | PTGES (0.38) | PTGESCYP3A4CYP3A5PPARG | |
| SCHEMBL4227238 | 0.69 | PTGES (0.41) | PTGESPTPN5CYP1A2PPARG | |
| SCHEMBL3002266 | 0.68 | PTGES (0.37) | PTGESPTPN5CYP3A4CYP3A5MCHR1 | |
| SCHEMBL3003384 | 0.68 | PTGES (0.37) | PTGESPTPN5CYP3A4CYP3A5MCHR1 | |
| SCHEMBL4701667 | 0.68 | PTGES (0.46) | PTGESPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197687-A1 | Indoles Useful in the Treatment of Inflammation | IDO1, IDO2, TPH1 | PTGES 33/4885MAP4K1 293/4885PTPN5 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.